

How Ebola and Marburg viruses battle the immune system

Mansour Mohamadzadeh^{**}, Lieping Chen[†], and Alan L. Schmaljohn^{*}

Abstract | The filoviruses Ebola and Marburg have emerged in the past decade from relative obscurity to serve now as archetypes for some of the more intriguing and daunting challenges posed by such agents. Public imagination is captured by deadly outbreaks of these viruses and reinforced by the specter of bioterrorism. As research on these agents has accelerated, it has been found increasingly that filoviruses use a combination of familiar and apparently new ways to baffle and battle the immune system. Filoviruses have provided thereby a new lens through which to examine the immune system itself.

Pantropic

Tending towards the capacity to infect a wide range of cells and organs.

Coagulopathy

Refers to a group of conditions of the blood-clotting system in which bleeding is prolonged and excessive.

Cell tropism

A virus's affinity for or tendency towards preferential infection of certain cells.

The known animal viruses are remarkably diverse in the ways in which they sustain themselves in nature, occasionally wreaking havoc in their preferred or accidental hosts. The immune system is central in this battle for survival, which is exemplified here by the cases of Ebola and Marburg virus (EBOV and MARV, respectively) infections in primates. In healthy but unvaccinated monkeys or humans infected with the most virulent strains of EBOV and MARV, the immune system loses the battle in nearly 90% of encounters, not slowly and inexorably as with some viruses, but in a matter of days (BOX 1). The reasons seem to reside in a complex series of interrelated viral and immune events.

As will be discussed, it seems that EBOV and MARV relentlessly infect cells of the monocyte–macrophage lineage, accelerating the release of pro-inflammatory cytokines, including tumour-necrosis factor (TNF) and interferon- γ (IFN γ), which in turn can disrupt the architecture of the vascular endothelium^{1,2} and other tissues (BOX 1; FIG. 1). The triggering of neutrophils and perhaps other polymorphonuclear leukocytes by interactions between viral particles and triggering receptors expressed on myeloid cells (TREMs) or Toll-like receptors (TLRs) provides another source of the copious amounts of inflammatory mediators produced as the viral burden increases during the course of infection. Along with fever, diarrhoea is a frequent symptom, and both dehydration and septicæmia become risks. Overshadowing everything is the inexorable replication of the virus, beginning in dendritic cells (DCs), monocytes and various types of macrophage, but proceeding to a more pantropic profile in which only certain cells — notably lymphocytes — are spared. In the case of MARV, hepatocytes are particularly susceptible,

elevated liver enzymes are among the first telling signs of disease and liver damage seems to account for much of the coagulopathy^{3,4}. Coincident with and underlying the unchecked viral replication, filoviruses deceive and dysregulate both innate and adaptive immune responses. Here, we describe recent findings pertinent to the clash between virus and host defences, summarize and briefly highlight the progress in the development of filovirus vaccines and therapeutics (BOX 2) and attempt to illuminate crucial areas in which questions and opportunities remain.

First encounters: receptor-mediated tropisms

The observed distribution of filoviruses in animals in the first days of infection^{5–7}, as well as various *in vitro* experiments, show that DCs, monocytes and macrophages are early targets of infection. This distribution occurs in a larger context in which filoviruses show diverse cell tropism and can eventually be found in numerous non-lymphocytic cell types in later stages of disease^{7,8}.

There seem to be several cellular receptors for filoviruses, and to the extent that they have been identified, they appear to be relatively nonspecific or pattern based (FIG. 2). Therefore, C-type lectins, such as DC-specific intercellular adhesion molecule 3 (ICAM3)-grabbing non-integrin (DC-SIGN; also known as CD209) or liver/lymph node-SIGN (L-SIGN; also known as CLEC4M), are sufficient to confer permissive filovirus glycoprotein-mediated infection⁹. Moreover, human macrophage C-type lectin specific for galactose/*N*-acetylgalactosamine (hMGL) that is expressed by cells of monocytic origin (such as immature DCs) also promotes filoviral entry¹⁰. Another C-type lectin, the asialoglycoprotein

^{*}US Army Medical Research Institute for Infectious Diseases, Frederick, Maryland, USA;
[†]Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Correspondence to M.M. and A.L.S.
e-mails:
Mansour.mohamadzadeh@amedd.army.mil;
Alan.Schmaljohn@amedd.army.mil
doi:10.1038/nri2098

| Report Documentation Page | | | Form Approved OMB No. 0704-0188 | | |
|--|------------------------------------|-------------------------------------|--|--|---------------------------------|
| Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. | | | | | |
| 1. REPORT DATE 1 APR 2006 | | 2. REPORT TYPE N/A | | 3. DATES COVERED - | |
| 4. TITLE AND SUBTITLE How Ebola and Marburg viruses battle the immune system. Nature Reviews of Immunology 7:556-567 | | | | 5a. CONTRACT NUMBER | |
| | | | | 5b. GRANT NUMBER | |
| | | | | 5c. PROGRAM ELEMENT NUMBER | |
| 6. AUTHOR(S) Mohamadzadeh, M Ghen, L Schmaljohn, AL | | | | 5d. PROJECT NUMBER | |
| | | | | 5e. TASK NUMBER | |
| | | | | 5f. WORK UNIT NUMBER | |
| 7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) United States Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD | | | | 8. PERFORMING ORGANIZATION REPORT NUMBER TR-06-116 | |
| 9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) | | | | 10. SPONSOR/MONITOR'S ACRONYM(S) | |
| | | | | 11. SPONSOR/MONITOR'S REPORT NUMBER(S) | |
| 12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited | | | | | |
| 13. SUPPLEMENTARY NOTES The original document contains color images. | | | | | |
| 14. ABSTRACT The filoviruses Ebola and Marburg have emerged in the past decade from relative obscurity to serve now as archetypes for some of the more intriguing and daunting challenges posed by such agents. Public imagination is captured by deadly outbreaks of these viruses and reinforced by the specter of bioterrorism. As research on these agents has accelerated, it has been found increasingly that filoviruses use a combination of familiar and apparently new ways to baffle and battle the immune system. Filoviruses have provided thereby a new lens through which to examine the immune system itself. | | | | | |
| 15. SUBJECT TERMS filovirus, Ebola, Marburg, review, glycoprotein, inflammatory responses, therapeutics, cytokines | | | | | |
| 16. SECURITY CLASSIFICATION OF: | | | 17. LIMITATION OF ABSTRACT SAR | 18. NUMBER OF PAGES 12 | 19a. NAME OF RESPONSIBLE PERSON |
| a. REPORT unclassified | b. ABSTRACT unclassified | c. THIS PAGE unclassified | | | |

Plasmacytoid dendritic cells (pDCs). A distinct subset of DCs that differ from conventional myeloid DCs in their capacity to produce copious amounts of interferon- γ in response to many viruses and Toll-like-receptor ligands.

Invariant natural killer T cell (iNKT cell). A cell type thought to be particularly important in bridging between innate and adaptive immunity. iNKT cells are typified by a capacity for self-recognition and rapid release of cytokines such as interferon- γ .

receptor that is expressed by hepatocytes, has specific affinity for the N-linked sugar chains with terminal galactose residues of MARV glycoproteins¹¹ and therefore initiates filoviral cell infectivity by facilitating viral cell entry. Conversely, the binding of filoviruses to C-type lectin molecules is significantly inhibited by the carbohydrate mannan, which indicates that the binding is due to the interaction between carbohydrate motifs on the surface of host cells and N-linked carbohydrate structures of glycoprotein on the filoviral surface. Recently, we also observed that a class of immunorecognition receptors known as TREMs, which are implicated in the amplification of septic shock and cell activation, might have a crucial early role in the interaction of filoviruses with neutrophils¹², monocytes and mature DCs.

Collectively, these observations about the binding of filoviruses to the C-type lectin and TREM receptors on cells of myeloid lineage are consistent with *in vivo* observations. Nevertheless, as filoviruses are pantropic and other infected cell types, such as endothelial and epithelial cells, do not express C-type lectins or TREMs, there might be other ubiquitous molecules, such as heparin-sulphate proteoglycan (HSPG; also known as SDC2)¹³ and folate receptor- α (REF. 14), involved in viral- and host-receptor-mediated entry.

If this complexity were not enough, it has been shown that filoviral glycoproteins are glycosylated differently, depending on the cells in which they are grown¹⁵, and that they bud from lipid rafts¹⁶ (a process in which viral particles might passively acquire host proteins that influence viral cell tropism). Further compounding the specificities of early interactions between viruses and cells, we recently observed that lactoferrin — an antimicrobial and immunoregulatory protein product that is released rapidly from preformed granules after

the binding of filoviruses to neutrophils — can act to enhance the uptake of filoviruses by immature DCs¹⁷. This observation was in direct contrast to a previous report in which lactoferrin inhibited the transmission of HIV *in vitro*¹⁸, but illustrates a larger principle: soluble products that accompany infection and inflammation *in vivo* might affect viral cell tropisms in ways that could be either helpful or damaging to the host.

Other molecules to consider in the engagement of MARV and EBOV with neutrophils and monocytes are TLRs, which are often central in the ability of innate immune cells to detect various pathogenic agents and to establish adaptive immune responses. So far, our preliminary data indicate that the expression of TLR1, the signalling of which converges with that of TLR2, was significantly increased on EBOV- and MARV-activated neutrophils, whereas the expression of other TLRs was not modulated¹⁷. Further studies are required to establish the pathogenic importance and the accessibility to intervention of these many early interactions between filoviruses and innate immune cells.

Dysregulation of initial innate immune activation

For the initiation of an effective antiviral immune response, early events are crucial in establishing an appropriate balance of stimulatory and inhibitory signals that act in conjunction with antigen recognition. Early innate immunity may be conceived in two general forms: first, as a relatively unspecific response involving pattern-recognition molecules, pro-inflammatory cytokines and cell-based antiviral functions; and second, as an orchestrated preparation for an antigen-specific response involving T cells and antibodies. In this early balance, filoviruses cause several significant perturbations (FIGS 1–3).

Recently, filoviruses were found to be capable of disabling at least some of the host IFN pathway: the filoviral protein VP35 prevents the production of type I IFNs (that is, IFN α and IFN β)^{19,20} and VP24 interferes with the ability of IFN α , IFN β and IFN γ to induce an antiviral state in cells²¹ (FIG. 2). Furthermore, because IFNs are crucial factors that are secreted abundantly by DCs of the monocytic lineage and plasmacytoid DCs (pDCs), and which are responsible for the efficient activation of natural killer (NK) cells, invariant NKT cells (iNKT cells) and T cells²², the effects of IFN antagonism are implicated not only in the high viral burdens late in the course of disease, but also in much of the early dysregulation of innate immunity. Another factor that suggests additional complexities of IFN gene regulation in response to viral infection is that the overall IFN response is not ablated *in vivo* — elevated levels of IFN are frequently noted in the blood during acute infection.

For T-cell responses, and therefore also for T-cell-dependent antibody responses, DCs are pivotal as antigen-presenting cells (APCs) — in addition to presenting peptide antigen on MHC molecules, DCs can provide either co-stimulatory or co-inhibitory signals through various ligands. The first indications of filovirus-mediated dysfunctions of DCs were typified by a generalized failure of EBOV- or MARV-infected human

Box 1 | Filovirus-disease basics

The filamentous single-stranded negative-sense RNA viruses belonging the family now called *Filoviridae* were first recognized only in 1967 (Marburg virus (MARV)) and 1976 (Zaire ebolavirus (ZEBOV) and Sudan ebolavirus (SEBOV)). Studies of ZEBOV have identified bats as potentially being among the natural hosts for ebolaviruses⁸⁷, and epidemiological evidence for MARV is also consistent with bats being the wildlife reservoirs of these viruses. The impact of these viruses on individual bats and bat populations is relatively unknown, but the consequences of filoviral infections in humans and non-human primates can be devastating: an acute disease with human mortality rates as high as 89% for sizeable outbreaks of either ZEBOV⁸⁸ or MARV⁸⁹. The viruses are apparently even more deadly in non-human primates than humans, with mortality rates approaching 100% in most non-human primate species, including the ebolavirus species for which human disease is rare (Ivory Coast ebolavirus) or has not been observed at all (Reston ebolavirus)⁹⁰.

In humans and monkeys, the hallmark of filoviral disease is unchecked viral growth that coincides with a relatively wide range of possible disease manifestations including fever, malaise, diarrhoea and vomiting, severe liver damage and various coagulation deficits that cause filoviruses to be categorized among the viral haemorrhagic fevers. The worst of the symptoms, including haemorrhage in a few individuals^{3,91}, seem to flow from a 'cytokine storm', a profuse release of pro-inflammatory cytokines⁵² (FIG. 1). In addition to cytokine effects on vascular permeability, causes of excessive bleeding can include plummets in platelet numbers, severe liver damage and the activation of tissue factor in monocytes and macrophages⁹². The time from infection to death is generally 1–2 weeks, with some variability depending on the virus and host species, as well as on initial dose⁹³. For survivors, recovery is a lengthy process.




Figure 1 | System overview of filoviral pathogenesis. Initially, productive infection (that is, that which results in more viral progeny) occurs primarily in dendritic cells (DCs), monocytes and macrophages. All infected cells can be at least partially impaired in interferon (IFN) production, but some important differences have been described between DCs and monocytes: monocytes respond with the production of pro-inflammatory cytokines, whereas DCs conspicuously lack such a response. Neutrophils are not productively infected, nor are lymphocytes, but neutrophils are activated by interaction with viral particles with resultant degranulation and shedding of triggering receptor expressed on myeloid cells 1 (TREM1). As viral burden increases, lymphocyte apoptosis and a generalized failure of specific immune responsiveness are observed; we propose these to be rooted in virally induced upregulation of co-inhibitory molecules (such as B7-H1) on DCs and monocytes, followed by interaction with programmed death 1 (PD1) receptors on T and B cells. Infection spreads to many cells including liver hepatocytes, and the increasing release of pro-inflammatory cytokines crosses a threshold from beneficial to potentially harmful inflammation, also degrading vascular epithelium. As repeated cycles of viral replication overwhelm and outpace a dysregulated adaptive immune response, elements of innate immunity and inflammation that are potentially helpful early in the response only add to the spiralled dysfunction as they collide with high viral burdens. Dysfunctions in DCs, monocytes and macrophages are particularly important for their secondary effects on innate and adaptive immune responses, inflammation and vascular integrity.

DCs to make the transition from the immature to the mature antigen-presenting DC stage, and a concomitant failure to produce an array of pro-inflammatory cytokines required for T-cell signalling^{20,23}. This selective loss of DC capabilities contrasted with earlier reports showing that monocytes and macrophages, like DCs, were susceptible to productive virus infection and were rendered incapable of IFN production, but, unlike DCs, responded by producing TNF and other pro-inflammatory cytokines^{1,24,25}. Therefore, a virus-induced deficit in the co-stimulatory properties of infected DCs

was implied, and was supported by the observation of a diminished capacity of such DCs to stimulate allogeneic T cells²⁰.

Interestingly, NK cells, which are an effective early defence against filoviruses in mice²⁶, might be among the host cells that are indirectly affected by the overall diminished synthesis of IFNs. Pre-treatment of animals with IFNs or IFN inducers before EBOV infection is considerably more effective in mice than in non-human primates²⁷; this indicates a decisive difference in the susceptibilities of different species to the effects

Box 2 | Therapies for filovirus infection

In simplest terms, therapeutic strategies are intended to slow the viral infection, treat symptoms and rely on immune clearance. Therefore, the clash between filoviruses and immune systems is expected to remain important even if effective therapies are developed. Currently, no effective therapies are available for human use, not even treatments useful shortly after exposure (and before disease symptoms develop), nor prophylactic measures. However, prospects for such therapies are encouraging, based on various preliminary successes in animal models (reviewed in detail elsewhere^{17,66,77,93}). In brief, these include the possibility of therapy with virus-specific antibodies; mitigation of virus-induced coagulation deficits using recombinant nematode anticoagulant protein c2; antisense compounds or small interfering RNAs to inhibit viral genes; inhibitors of putative specific or nonspecific viral receptors on susceptible cells; interferons; and the possibility of using specific peptides to mitigate adverse consequences of interactions between filoviruses and neutrophils. Other potential vulnerabilities of the viruses, such as the viral fusion domain, cellular pathways required for viral exit or proteolytic cascades required for entry, are also open to therapeutic exploitation; even post-exposure vaccination shows promise.

of IFN antagonism that results from filoviral infection. Moreover, the effects of VP35, VP24 and perhaps other filoviral proteins might prove even more pleiotropic — not only IFN-related genes but also multiple cellular genes were perturbed by filoviral infection of hepatocytes, many of these genes were differently dysregulated depending on the filovirus species²⁸. Further, it was shown previously that interleukin-8 (IL-8; also known as CXC-chemokine ligand 8 (CXCL8)), an α -chemokine produced abundantly during filoviral infection, antagonizes the antiviral activity of IFN α by inhibiting the function of 2',5'-oligoadenylate synthetase (OAS) in encephalomyocarditis virus (EMCV) infection²⁹. Accordingly, it may be worthwhile to explore the role of IL-8 in filoviral infections.

Further contributing to the initial immune response, viral replication in monocytes and macrophages continues unabated, enabled by the filoviral IFN-antagonist proteins and accompanied by the secretion of other non-inhibited pro-inflammatory cytokines. Viral particles, in turn, are able to trigger polymorphonuclear leukocytes (such as neutrophils) to expel the contents of their preformed granules and enter a state of activation¹². Such early inflammatory responses are not extraordinary and might even be helpful in shaping normal immune responses³⁰, but might also exacerbate an underlying early immune response dysfunction that originates principally in DCs.

Also potentially important are the roles of various cellular proteases (for example, cathepsins, furins and sheddases) (FIG. 2). By affecting either viral entry^{31,32} or exit^{33,34}, these and other proteases could influence viral cellular tropisms and perhaps interactions between glycoprotein domains and antibodies (FIGS 2,3). Moreover, Barrientos and Rollin reported recently that endosomal proteolytic enzymes, including cathepsins, were released from EBOV-infected cells, that this release was more pronounced in cells infected with a more lytic variant of EBOV and that cytopathicity was diminished by the cathepsin inhibitor E64 (REF. 35); from this, they inferred a possible role of proteases in pathogenic events including vascular leakage.

Related to all these observations is the abundance of all known cathepsins, especially cathepsin D, cathepsin E and cathepsin S, in monocytes, macrophages and DCs³⁶, which are cells that are important owing to their great susceptibility to filoviral infection and also owing to the role of their proteases in antigen processing. Interestingly, a variant of EBOV that is resistant to furin cleavage (the same variant noted as being more cytopathic *in vivo*) was recently reported to be similar to wild-type EBOV in its virulence to non-human primates³⁷.

Disordering of adaptive immunity

Dysfunctional antigen presentation. Generally, properly activated DCs are tailored to evoke optimal activation of T cells; however during filoviral infection, the functions of DCs might be reversed, as they are first dependant on sensing pathogens through pattern-recognition receptors, and second they are dependant on the signals delivered to them by the viruses. Accordingly, filoviruses have been shown to silence active co-stimulatory molecules in DCs (such as CD40, CD86 and IL-12)^{20,23}, which indicates that infected DCs enter a stage of cellular dysfunction. In a basic outline, the adaptive immune response can be characterized by the four-part sequence of initial activation, antigen-specific expansion (proliferation), contraction (downsizing) and establishment of immune memory. Filoviruses seem to foster dysregulation of the first three stages and even the fourth might prove problematic for filovirus vaccine development.

Here, we consider that the effects of filoviruses on DCs and monocytes seem to be even more pernicious than those that would result from just the failure to deliver regulated positive immune signals, and that these effects are possibly a result of active co-inhibition of the immune response. The first suggestions of this concept came from the observed clinical manifestations of advanced filoviral diseases in humans³⁸ and monkeys³⁹, in which there were pronounced indications of apoptotic death of lymphocyte populations in peripheral blood and lymph nodes. Because contraction — the loss of some 95% of cells that had proliferated in response to antigenic stimulation — is a normal part of immune homeostasis⁴⁰, it was unclear at first the degree to which these observations were exaggerated in filoviruses compared with other acute infections. However, the observation aligns with the emerging understanding of co-inhibitory immune signalling, and gives mechanistic support to the hypothesis that filoviruses are among the viruses that can, at least in some species, upset and disorder the natural processes of immune-cell proliferation and contraction.

Role of co-inhibitory molecules in infection. Ordinarily, T-cell co-signalling pathways are stimulated shortly after viral infection — for example, through interactions between the well-characterized co-stimulatory molecule CD28, which is expressed by T cells, and B7-family ligands CD80 and CD86, which are induced on functioning and mature DCs — and they are responsible for activating what is at first a relatively rare population of antigen-specific T cells. Conversely, these molecules can




Figure 2 | Viral and cellular events in filoviral infection. Central to filoviral disease is the rapidly increasing viral burden, which can peak at more than 10^9 plaque-forming units (PFUs) in tissues 7–10 days after infection of non-human primates. Several possible cellular receptors for viral entry have been described; these studies have suggested that there is a redundancy in the receptors used for viral entry and that there are partial biases towards the infection of certain cells. Viral entry involves the stepwise proteolysis of viral glycoprotein followed by membrane fusion and disassembly of the elongated matrix-nucleoprotein complex, which contains the other six proteins encoded by the viral genome. In the transcription of mRNAs from the negative-strand genome template, the glycoprotein gene of Ebola virus (EBOV; but not Marburg virus (MARV)) undergoes editing to produce soluble variants of glycoprotein as well as the membrane-bound form, which trimerizes to form the viral envelope spikes. Additional forms of soluble glycoprotein arise post-translationally from proteolysis and/or failure to establish disulphide bonds between naturally occurring glycoprotein fragments GP1 and GP2; the role of soluble forms of glycoprotein in confounding the immune response remains hypothetical. The unchecked replication in primate cells can be explained in large part by the recently described capacity of VP35 to inhibit interferon (IFN)-regulatory factor 3 (IRF3) and thereby prevent infected cells from synthesizing type I IFNs¹⁹, and the ability of VP24 to interrupt the nuclear accumulation of tyrosine-phosphorylated STAT1 (signal transducer and activator of transcription 1), rendering cells insensitive to the antiviral effects of interferons²¹. EBOV and MARV are cytopathic in most cell types, but direct viral damage to cells is slow enough that host-cell pathways, including protein synthesis, continue to function for many hours, albeit abnormally. After completing the cycle and initiating another, filamentous virions assemble at areas at the plasma membrane called lipid rafts, which are rich in a subset of host-cell proteins. APC, antigen-presenting cell; DC-SIGN, dendritic-cell-specific intercellular adhesion molecule 3 (ICAM3)-grabbing non-integrin; GP, glycoprotein; TLR, Toll-like receptor.




Figure 3 | Effects of filoviral infection on immunological events. Both antibody and T-cell responses (as well as innate effectors such as natural killer (NK) cells) are relevant to immunity and act together to promote viral clearance. Whereas high total antibody levels against glycoprotein are predictive of immunity, serum antibodies of the kind that prevent viral entry (that is, the most familiar type of neutralizing antibody) have proved difficult to measure, especially against Marburg virus (MARV), have been poor correlates of immune protection in vaccination and passive transfer studies. Antibodies might also suppress viral burden by other means, for example, by directing lysis of glycoprotein-expressing cells or disrupting virion formation and release at the cell surface. Hypothetically, soluble forms of glycoprotein are detrimental, having the capacity to sequester antibodies that would otherwise have antiviral effects. T-cell responses are impaired in infected humans and monkeys. Possibly explaining some of the immune deficit, infected human and monkey dendritic cells (DCs) are not only disabled in their interferon (IFN) pathways but are impaired in their capacities to differentiate, express co-stimulatory molecules and produce a normal array of cytokines. Simultaneously, infected DCs and monocytes may express more of the co-inhibitory molecule B7-H1, prompting an increase in its apoptosis-linked receptor programmed cell death 1 (PD1) on T cells. In the resulting model, the adaptive immune response to filoviruses in unvaccinated animals is baffled not only by IFN antagonism in DCs and monocytes but by the viral dysregulation of pro-inflammatory cytokines, co-stimulatory and co-inhibitory molecules. APC, antigen-presenting cell; CD40L, CD40 ligand; CTLA4, cytotoxic T-lymphocyte antigen 4; GP, glycoprotein; IL-12, interleukin-12; NP, nucleoprotein; TCR, T-cell receptor.

interact with cytotoxic T-lymphocyte antigen 4 (CTLA4) and thereby induce T-cell silencing. Such co-stimulatory and co-inhibitory signals have also been ascribed to other newly described B7-family molecules that are postulated to be crucial in regulating the dialogue between APCs and T cells. This newly described class of the B7 family (including B7-DC (also known as PD-L2 and PDCD1LG2), **B7-H1** (also known as PD-L1 and CD274), B7-H2 (also known as ICOSLG), B7-H3 (also known as CD276) and B7-H4 (also known as VTCN1)) and their receptors (such as programmed cell death 1 (PD1; also known as PDCD1) and inducible T-cell co-stimulator (ICOS)) control T-cell responses in both a positive and a negative manner in cancer and infectious diseases^{41,42}. In general, co-inhibitory pathways are considered to

be among the host mechanisms required to institute or restore homeostasis, minimizing harmful self recognition or re-balancing the system after a robust response to foreign antigen. However, cancer, infectious diseases or autoimmune diseases such as rheumatoid arthritis exploit these processes, and this results in immune evasion, autoreactivity or dysfunctions of immunity, such as anergy and exhaustion⁴¹.

How might viral-mediated dysfunction of DCs and monocytes be manifested not only as poor positive signalling but as active inhibition of immune responsiveness? An interaction that typifies such inhibition is one that occurs between B7-H1, a co-inhibitory molecule expressed on DCs and monocytes (and many other cells), and its ligand PD1, expressed on activated T and

Exhaustion

The condition of functionally impaired antigen-specific T cells, typified by elevated surface expression of PD1.

B cells. Overexpression of B7-H1 typically precedes the upregulation of PD1 on activated T cells. PD1 then transmits elevated negative signals into T cells, which, in collaboration with unregulated inflammatory cytokines (such as TNF and IFN γ), may effectively establish exhaustion, anergy, and subsequent suppression and apoptosis of these cells^{40,41,43}. Indeed, we have previously shown that B7-H1 not only controls CD8⁺ T-cell homeostasis, but also contributes selectively to the deletion of intrahepatic CD8⁺ T cells⁴⁴. Iwai *et al.* also showed correlatively that PD1-deficient mice were more resistant to acute hepatic damage owing to adenovirus infection⁴⁵. Moreover, Barber *et al.* recently showed that although most lymphocytic choriomeningitis virus (LCMV)-specific CD8⁺ T cells in persistently infected mice express activation molecules (such as CD69 and CD44), these cells are functionally exhausted and therefore do not exert their antiviral effector function⁴⁶. Barber *et al.* further showed that PD1 is expressed on impaired LCMV-specific CD8⁺ T cells and that blockage of the PD1 interaction with B7-H1 during chronic LCMV infection reanimates these cells and induces clearance of LCMV⁴⁶. These trends have been confirmed in human studies showing that elevated levels of B7-H1 (REF. 47) and PD1 (REFS 48,49) are associated with T-cell exhaustion and depletion in HIV, and T-cell function can be restored *in vitro* by using B7-H1-specific antibody to antagonize the co-inhibitory interaction between B7-H1 and PD1. The commonality between these and other earlier observations of the importance of co-inhibition mediated by B7-H1–PD1 interactions is that they involve chronic conditions.

Returning to the particular case of filoviruses and the acute diseases that they cause, recent investigations in individuals and non-human primates infected with filoviruses have demonstrated the gradual disappearance and deletion of CD8⁺ T cells and NK cells^{38,50}. That little or no immune response to the virus is observed in humans and non-human primates before they succumb to disease^{4,6,51} is consistent with the incapacity of infected DCs to regulate their CD40 and CD86 molecules, and the coincident failure of DCs to secrete IL-12 and other cytokines^{20,23}. The naturally increased expression of B7-H1 in liver macrophages and parenchymal cells — thought to explain, at least in part, the poor immune responses to a wide range of antigens typically observed in the liver⁴⁴ — is particularly intriguing in view of the hepatotropic manifestation of filoviral disease (FIG. 1, BOX 1). For now, because immune dysfunction that is directly attributable to the rapid triggering of co-inhibitory pathways is only beginning to be implicated in acute viral infections⁴², the importance of this pathway in filovirus pathogenesis remains speculative.

Paradoxically, the role of IFN γ , which is secreted copiously in the plasma of infected individuals and non-human primates late in filovirus infection^{8,52}, might be more detrimental than helpful, as any regulatory effects of IFN γ on CD8⁺ T cells must be proximal to initial activation; otherwise, this cytokine might induce pro-apoptotic effects that result in cell-population contraction and T-cell apoptosis⁵³. Although CD8⁺

T cells have mechanisms to evade this cytokine by downregulating the IFN γ receptor subunit 2 to complete their cellular expansion⁵⁴, the rapid filoviral invasion might induce other unknown signalling events that might close the window of opportunity to promote functional CD8⁺ T cells. Moreover, what are the roles of other regulatory and inflammatory molecules (such as IL-10, transforming growth factor- β 1 (TGF β 1) and IL-17), which are abundantly secreted during the induction phase of filoviral infection? Answers will come as future studies shed light on additional aspects of filoviral infection and disease.

Other immune-component cells. In addition to NK cells, filoviruses might also trigger CD1d-restricted *i*NKT cells^{55,56}, and even IFN-producing killer DCs (IKDCs), a newly described DC subset in which the cells have characteristics of both DCs and NK cells⁵⁷. The resulting signalling cascade would involve massive detrimental inflammation, dysfunction of DCs, retention of DCs in an immature stage and abolition of the co-stimulatory function of DCs; therefore, NK cells or *i*NKT cells would not be able to exercise effective responses to invading filoviruses. Worse, on receiving co-inhibitory signals, these cells might contribute to the production of copious amounts of IFN γ , which can induce more B7-H1 (REF. 58) and thus facilitate further cellular anergy and subsequent NK-cell deletion^{38,50}. Conversely, as filovirally infected DCs retain an immature phenotype, these cells could be eliminated by the NK-cell-dependent Nkp30 trigger receptor⁵⁹. Further fundamental questions remain to be addressed to understand what mediates the impaired cytotoxicity of NK cells, *i*NKT cells or even IKDCs, and to discern the factors that are induced by dysfunctional DCs and the strong inflammatory microenvironment that occurs early during the infection, wherein these cells reside.

Collectively, therefore, much remains to be clarified with respect to the relative importance of new or dysregulated pathways in the innate and adaptive immune responses to filoviruses. However, recent studies point towards what might be reversible dysfunctions and therefore to new therapeutic rationales to restore balance and favour an animal's survival.

Inferences from vaccines and therapies

Filovirus antigens. Filoviruses belong to the order of *Mononegavirales*, which includes respiratory syncytial, measles, mumps, parainfluenza and rabies viruses. As antigens, filoviruses have a uniquely filamentous structure, but at a glance otherwise seem to be unexceptional among similar viral genera. That is, from a single 19-kilobase strand of negative-sense RNA, the viral replicase complex makes mRNA to encode relatively few (seven or more) proteins (FIG. 2). Of these, only one (the glycoprotein) is known with certainty to appear on virion surfaces (and also on the surface of infected cells), where it can serve as a target for antibodies, some of which might mediate protection. In theory, any of these viral proteins could be recognized by T cells; indeed, in the case of a mouse-adapted variant of

Anergy

The impaired or absent ability of an immune cell to respond to specific antigens.

Table 1 | Marburg- and Ebola-virus vaccines containing glycoprotein

| Vaccine type* | Comments | Principal concerns | Refs |
|--------------------------------|---|--|-----------------|
| Killed filovirus | Early vaccine efforts and recent proofs of concept; inadequate efficacy [‡] in non-human primates | Safety [§] ; potency [¶] ; observed disease exacerbation | 67,68,94 |
| Live attenuated filovirus | Only as proofs of concept with natural or passaged viruses; high risk could theoretically be mitigated by reverse-genetics approach | Live vaccine; balance of safety and potency incomplete attenuation or reversion | 94-97 |
| Live vaccinia vectored | Proof of concept, deprioritized along with other live pox-vectored vaccines | Live vaccine balance of safety and potency; vector immunity [¶] | 67 |
| Expressed protein, baculovirus | Incomplete efficacy in guinea pigs, no reported efficacy in non-human primates | Potency, adjuvant requirement; altered glycosylation | 69,94,98 |
| Defective VEE replicon | Excellent efficacy in rodents, first demonstration of efficacy against MARV in non-human primates, minimum protective dose about 10 ⁸ IU in non-human primates | Vector immunity; safety at doses high enough to achieve potency | 4,62,94 |
| DNA | Adequate in rodents; incomplete non-human-primate efficacy with MARV and none reported with EBOV; touted for immunological priming | Potency | 63,78,79, 94,99 |
| Defective adenovirus | Excellent efficacy if doses 10 ¹⁰ IU or higher. First demonstration of non-human-primate efficacy with EBOV, including one-dose protection | Vector immunity, safety at doses high enough to achieve potency | 65,78, 100 |
| Virus-like particles | Good rodent efficacy; safety and possible potency advantage compared with killed virus particles | Potency; adjuvant requirement | 101 |
| Live recombinant VSV | Excellent rodent and non-human-primate efficacy with both MARV and EBOV; single-shot vaccine, rapid immunity; no overt illness from live vaccine itself; in recombinant vaccine, filovirus glycoprotein replaces VSV glycoprotein | Live vaccine; balance of safety and potency; environmental release ^{**} | 64,82 |
| Live recombinant parainfluenza | Good efficacy against Ebola virus in guinea pigs and non-human primates; contains both parainfluenza virus and EBOV glycoproteins | Live vaccine; balance of safety and potency; environmental release | 80,81 |

*Vaccines are listed in approximate chronological order of their first public descriptions of significant efficacy; the first four genetic vaccines (vaccinia through DNA) became known roughly simultaneously in 1996. [‡]Here, vaccine efficacy for filoviruses is operationally defined by prevention of disease in a susceptible animal inoculated with an amount of virus (usually 10² to 10³ plaque-forming units \approx LD₅₀) associated with ordinary exposure. [§]Safety concerns might arise in manufacture itself (as with killed viruses), but more often refer to anticipated difficulties in achieving manufacture suitable for regulated human trials, and then an expectation of adequate safety in large trials and diverse populations. [¶]Potency is interpreted as the capacity to elicit a protective immune response as defined by a quantitative assay that correlates with protection. ^{¶¶}For live and replication-defective recombinant vaccines, vector immunity refers to pre-existing immunity to the vaccine vector, which can arise naturally or by successive vaccination with the same vector, and acts to diminish the effective dose and therefore potency of vaccine delivered. ^{**}Environmental release is an additional concern for new replicating vaccines, requiring assessment of possible consequences of vaccine transmission to humans or other animals, including arthropods. EBOV, Ebola virus; IU, infectious units for replication-defective vectors that infect cells without further spread; MARV, Marburg virus; VEE, Venezuelan equine encephalitis virus; VSV, vesicular stomatitis virus.

Zaire ebolavirus (ZEBOV), six of the seven existing proteins (the replicase protein L was not examined) were observed to evoke protective responses in at least one strain of mouse, with demonstrable T-cell responses associated with survival, and, in some cases, effective on adoptive transfer^{60,61}. However, in guinea pigs challenged with MARV, only viral glycoprotein, nucleoprotein and VP35 afforded some measure of protection when used as vaccines in a replicon-based vector system⁴. In guinea pigs vaccinated and then challenged with ZEBOV, viral glycoprotein was a superior protective antigen, with nucleoprotein providing no⁶² or equivocal⁶³ protection. In the case of non-human primates that had been vaccinated and then challenged with either MARV or ZEBOV, viral glycoprotein has proved to be necessary and sufficient as a vaccine component. Nucleoprotein alone provided incomplete protection in monkeys infected with MARV, whereas viral glycoprotein by itself (or admixed with nucleoprotein) prevented illness and death in six out of six infected animals⁴. Similarly, the first successes in protecting non-human primates against ZEBOV were with a vaccine containing glycoprotein; subsequent studies showed glycoprotein by itself to be sufficient^{64,65}, and there are no published data

to indicate that there are any other proteins capable of protecting non-human primates against ZEBOV in the absence of glycoprotein.

It is frequently observed that filoviral vaccines and therapies that succeed in rodents are far less successful in non-human primates^{4,8,66-68}. Therefore, the collective and empirical experience with vaccines tested for the capacity to protect against either MARV or ZEBOV in the most susceptible and perhaps most relevant (to humans) host — non-human primates — has revolved entirely around vaccines that contain glycoprotein (TABLE 1). Whether filovirus vaccines for non-human primates can be improved by removing some regions of glycoprotein remains to be shown.

Humoral immunity against filovirus infection.

Mechanistically, most of the available evidence indicates that both antibody and T-cell responses of appropriate kind and magnitude are required for robust protection against filoviruses, especially in non-human primates. Support for the involvement of antibodies takes several forms. Foremost, passive immunotherapy with convalescent sera or monoclonal antibodies has been shown to mitigate or prevent MARV and ZEBOV disease in

guinea pigs and mice^{69–72}, delay viraemia and death in non-human primates²⁷ and possibly improve clinical outcomes in humans^{73,74}. Moreover, B-cell-deficient mice were impaired in their ability to eliminate ZEBOV⁷⁵. Further, the empirical observation of glycoprotein as the most effective protective antigen in non-human primates argues indirectly that humoral immunity is relevant, and protection has been associated with total antibody levels^{4,64,65}.

On the other hand, antibody alone has not yet been shown to be sufficient to protect non-human primates from lethal infection with more than a few infectious viruses^{27,76}, and the human clinical data were equivocal because treatments were performed in uncontrolled emergency situations. It has been confounding to some researchers that neutralization of filoviruses by antibodies — as measured by a reduction in viral infectivity after admixture with antibodies — has proved to be a completely unreliable *in vitro* predictor of antibody or vaccine effectiveness^{4,64,70,76}. Others researchers point to a rich history of antibodies shown to protect in ways other than what is popularly understood as neutralization⁷⁷. Some of the mechanisms by which such non-neutralizing antibodies might control viral burden are shown in FIG. 3 and are briefly reviewed elsewhere⁷⁷. It remains unclear whether monoclonal antibodies can be found to act by themselves therapeutically in non-human primates, whether other strategies will prove more effective (BOX 2), or whether combination therapies, perhaps including antibodies, will be required.

Cellular immunity to filovirus infection. The role of T cells in successful vaccination against filoviruses is similarly persuasive, yet insufficient to attribute this protection wholly to cellular immunity. T-cell involvement has been documented most clearly in the mouse model of ZEBOV, in which cytotoxic T cells specific for nucleoprotein were protective on adoptive transfer⁶¹, CD8⁺ T-cell-deficient mice were more susceptible to lethal challenge⁷⁵ and at least five cytoplasmic ZEBOV proteins (presumably inaccessible to antibodies) were independently capable of eliciting both T cells and protective immunity⁶⁰. Internal nucleoprotein and VP35 were capable of inducing significant protection in MARV-infected guinea pigs⁴, and the nucleoprotein-specific protection in non-human primates was probably due to T cells⁴. In an effort to discern how mice resist ZEBOV, a case was made that not only CD8⁺ T cells but also CD4⁺ T cells are crucial in viral clearance⁷⁵, a finding that would be among those expected if glycoprotein-specific antibodies were important. Reliable quantification of T-cell responses in a way that correlates with protection has not been achieved with filoviruses in guinea pigs or non-human primates, but when serious efforts to measure T-cell responses have been undertaken, it has been routinely observed that filovirus-antigen-specific T cells can be found in animals that are shown subsequently to be immune to lethal infection⁷⁸.

A collective analysis of the vaccine studies in TABLE 1 indicates that the magnitude of the total glycoprotein-specific antibody response is associated with protection, a measure which presumably correlates not only with

types of antibody that are protective but also with T cells for which suitable assays remain elusive. Put most simply, higher doses of vaccine seem to evoke greater total immune responses, along with a protection that is more rapidly acquired and more complete than that obtained with replication-defective vaccines given at much lower doses. A recent report with a recombinant adenovirus that expresses the ZEBOV glycoprotein, in which the minimal protective dose of 10¹⁰ particles is described as a 'low dose', affirms that protection is dependent on the vaccine dose⁶⁵, and might explain why replicon-based vaccines given at much lower doses have not been uniformly successful⁶⁷ and DNA vaccines have been only partially effective⁷⁹. Live vesicular stomatitis virus (VSV)⁶⁴ or parainfluenza virus^{80,81} recombinants, which show considerable promise in protecting non-human primates from filoviral infection, presumably generate high amounts of viral glycoprotein antigen *in vivo*. Herein resides a most familiar challenge of vaccine licensure: the achievement of a suitable balance between vaccine potency and vaccine safety.

Mechanistically, additional immunological and virological puzzles have been exposed by recent demonstrations of protective effects of vaccinating rodents or primates with replication-competent vaccines shortly before or shortly after infection with MARV⁸² or EBOV⁸³. Surmising that protective mechanisms in this exceptional circumstance could be 'multifactorial', Feldmann *et al.* proposed as possible explanations not only antibodies and T cells, but also NK cells, innate immune responses and viral interference (attenuated-vaccine virus out-competing virulent filoviruses at the cellular level)⁸³. Hypothetically, well-balanced innate and adaptive immune responses against the replicating vaccine (here in a VSV vector) occur in parallel with otherwise dysfunctional responses to filoviruses, suppressing and ultimately eliminating both viruses. Whether replication-defective filovirus vaccines may have similar protective effects if given shortly before or after filoviral infection is not yet clear.

Difficulties presented to the immune system by filoviral glycoprotein antigens. If it were not difficult enough for the immune system to repel filoviral attack, viral glycoprotein presents an array of deceptions and challenges. Summarized in TABLE 2, the confounding traits of viral glycoprotein influence the rational design and improvement of vaccines. Moreover, although several experimental vaccine approaches have been shown to be capable of eliciting the robust immune responses necessary to protect non-human primates against either EBOV or MARV disease, it remains to be determined whether appropriate immunological memory (as defined by long-term protection) will be established by the same vaccines. As for the immune systems of the unvaccinated primates exposed to glycoprotein for the first time, and in the context of all the aforementioned advantages held by the infectious virus, it is perhaps most impressive that the immune response occasionally prevails, and many individuals and a few non-human primates do survive.

Table 2 | Evasion and deception strategies available to filovirus glycoprotein

| Observation | Comments | Immune consequences | Refs |
|---|--|--|--------------------|
| Antigenic variation | Variability between isolates and species is concentrated in the central 'mucin-like' portion of GP, which, after cleavage to GP1–GP2 becomes the distal aspect of the GP spike | Negligible cross-reactivities of antibodies and no cross-protection between viral species, limited cross-reactivities of antibodies among disparate isolates of MARV | 15,69,70, 102,103 |
| Abundant N- and O-linked glycosylation | Concentrated in mucin-like domain; variations in glycosylation, some due to cell type | Epitope masking; phenotypic variation; viral tropism for cells having lectin-like receptors (such as DCs and monocytes) | 11,15, 69,104 |
| GP shedding | Failure of disulfide-bond formation results in GP1 shedding; cell proteases cause an alternative form of shedding of GP1–GP2 ectodomain | Soluble antigens compete for antibodies otherwise effective against viruses or infected cells | 33 |
| GP gene editing | Observed in EBOV, not MARV; genome encodes mRNA for a truncated, frame-shifted version of GP (sGP) | Similar to GP shedding, but with added twists of truncation, frame-shift and different glycosylation of sGP | 97,105, 106 |
| Structural masking of receptor-binding and fusion domains | Key functional domains are proximal to membrane, exposed only transiently upon entry | Antibodies underrepresented and possibly ineffective against important functional regions | 32, 107–109 |
| Promiscuous binding to cells | GP apparently binds multiple cell receptors with varying efficiencies; filamentous viral structure might favour effectiveness of low-affinity interactions | Problematic for antibodies to block initial interactions between viruses and a variety of cells and receptors | 5,7,15, 73,85,96 |
| Triggering of cytokine release | GP on viral particles is sufficient to trigger intracellular cascades, granule release, cytokines | Disorienting milieu for initiation of balanced immune response | 12,20,23, 25,51,52 |
| Toxicity of GP for cells | Might be less of a problem <i>in vivo</i> than with <i>in vitro</i> expression systems | Could affect performance or manufacture of genetic vaccines | 97,110, 111 |
| Immunosuppressive domain | Tenuous observation, with importance still neither confirmed nor refuted | Remains a possible explanation for some dysregulations now attributed to whole GP | 68,112 |

EBOV, Ebola virus; GP, glycoprotein; MARV, Marburg virus; sGP, soluble GP.

Concluding hypotheses and prospects

It is becoming progressively clearer how EBOV and MARV overwhelm host defences and cause disease by dysregulating and defeating first the innate and then the adaptive immune systems of primates and humans (FIGS 1–3). Each of several properties of the viruses are probably required to account for their profound virulence, and it has already been observed that changes in the IFN antagonists VP35 and VP24, the glycoprotein, the viral replicase or the nucleoprotein can diminish filovirus virulence in the mouse model⁸⁴. It remains to be explained why the profound virulence, characteristic of all members of the diverse family *Filoviridae*, is apparently limited to primates⁸⁵, which are presumably accidental hosts for the viruses. Nonetheless, our increased understanding of the events involved in filoviral infection points towards new possibilities in shifting the advantage to the immune system. In general, the many therapeutic approaches designed to slow viral replication can allow the immune system to gain additional time to mount an effective defence, but such intervention might be required early, even before symptoms develop.

Other interventions, intended to manage disease symptoms, might also provide the immune system with additional time. One possibility that has emerged is an intentional intervention in the early inflammation and co-inhibitory dialogue between DCs and T cells and even other immune-cell types, for example, with specific tolls (such as B7-H1-specific antibody) to prevent exaggerated regulatory signals from inducing T-cell exhaustion; this hypothetical means to control viral clearance has precedence in cancer, HIV and, more recently, in a mouse model of chronic lymphocytic choriomeningitis virus infection^{41,43,46,86}. Improvements in filoviral vaccine development strategies might follow from the ongoing identification and exploitation of glycoprotein components that evoke protective immunity. On the whole, the efforts to provide medical countermeasures for these deadly but relatively rare viruses seem poised to tell us a great deal not only about these particular viruses, but more generally about the immune responses to acute viral infections, and how to shift the battle in favour of immunity and survival.

1. Feldmann, H. *et al.* Filovirus-induced endothelial leakage triggered by infected monocytes/macrophages. *J. Virol.* **70**, 2208–2214 (1996).
2. Wahl-Jensen, V. *et al.* Role of Ebola virus secreted glycoproteins and virus-like particles in activation of human macrophages. *J. Virol.* **79**, 2413–2419 (2005).
3. Slenczka, W. G. The Marburg virus outbreak of 1967 and subsequent episodes. *Curr. Top. Microbiol. Immunol.* **235**, 49–75 (1999).

4. Hevey, M., Negley, D., Pushko, P., Smith, J. & Schmaljohn, A. Marburg virus vaccines based upon alphavirus replicons protect guinea pigs and nonhuman primates. *Virology* **251**, 28–37 (1998).
This reference provides a seminal demonstration of glycoprotein as a necessary and sufficient protective antigen, and of a vaccine capable of providing robust

immunity against filovirus disease in non-human primates.

5. Ryabchikova, E. I., Kolesnikova, L. V. & Luchko, S. V. An analysis of features of pathogenesis in two animal models of Ebola virus infection. *J. Infect. Dis.* **179** (Suppl. 1), 199–202 (1999).
6. Ignatyev, G. M. Immune response to filovirus infections. *Curr. Top. Microbiol. Immunol.* **235**, 205–217 (1999).

7. Geisbert, T. W. *et al.* Pathogenesis of Ebola hemorrhagic fever in cynomolgus macaques: evidence that dendritic cells are early and sustained targets of infection. *Am. J. Pathol.* **163**, 2347–2370 (2003). **This paper reports distinctive *in vivo* studies in which early viral events in non-human primates were tracked in serial sampling experiments.**
8. Feldmann, H., Jones, S., Klenk, H. D. & Schnittler, H. J. Ebola virus: from discovery to vaccine. *Nature Rev. Immunol.* **3**, 677–685 (2003).
9. Simmons, G. *et al.* DC-SIGN and DC-SIGNR bind Ebola glycoproteins and enhance infection of macrophages and endothelial cells. *Virology* **305**, 115–123 (2003).
10. Takada, A. *et al.* Human macrophage C-type lectin specific for galactose and N-acetylgalactosamine promotes filovirus entry. *J. Virol.* **78**, 2943–2947 (2004).
11. Becker, S., Spiess, M. & Klenk, H. D. The asialoglycoprotein receptor is a potential liver-specific receptor for Marburg virus. *J. Gen. Virol.* **76**, 393–399 (1995).
12. Mohamadadeh, M. *et al.* Activation of triggering receptor expressed on myeloid cells-1 on human neutrophils by Marburg and Ebola viruses. *J. Virol.* **80**, 7235–7244 (2006).
13. Bobardt, M. D. *et al.* Syndecan captures, protects, and transmits HIV to T lymphocytes. *Immunity* **18**, 27–39 (2003).
14. Chan, S. Y. *et al.* Folate receptor- α is a cofactor for cellular entry by Marburg and Ebola viruses. *Cell* **106**, 117–126 (2001).
15. Feldmann, H., Nichol, S. T., Klenk, H. D., Peters, C. J. & Sanchez, A. Characterization of filoviruses based on differences in structure and antigenicity of the virion glycoprotein. *Virology* **199**, 469–473 (1994).
16. Bavari, S. *et al.* Lipid raft microdomains: a gateway for compartmentalized trafficking of Ebola and Marburg viruses. *J. Exp. Med.* **195**, 593–602 (2002).
17. Mohamadadeh, M., Chen, L., Olinger, G. G., Pratt, W. D. & Schmaljohn, A. Filoviruses and the balance of innate, adaptive, and inflammatory responses. *Viral Immunol.* **19**, 602–612 (2006).
18. Groot, F. *et al.* Lactoferrin prevents dendritic cell-mediated human immunodeficiency virus type 1 transmission by blocking the DC-SIGN–gp120 interaction. *J. Virol.* **79**, 3009–3015 (2005).
19. Cardenas, W. B. *et al.* Ebola virus VP35 protein binds double-stranded RNA and inhibits $\alpha\beta$ interferon production induced by RIG-I signaling. *J. Virol.* **80**, 5168–5178 (2006). **Along with reference 21, this paper provides recent mechanistic data and an overview on IFN antagonists encoded by filoviruses.**
20. Bosio, C. M. *et al.* Ebola and Marburg viruses replicate in monocyte-derived dendritic cells without inducing the production of cytokines and full maturation. *J. Infect. Dis.* **188**, 1630–1638 (2003).
21. Reid, S. P. *et al.* Ebola virus VP24 binds karyopherin $\alpha 1$ and blocks STAT1 nuclear accumulation. *J. Virol.* **80**, 5156–5167 (2006).
22. Marrack, P., Kappler, J. & Mitchell, T. Type I interferons keep activated T cells alive. *J. Exp. Med.* **189**, 521–530 (1999).
23. Mahanty, S. *et al.* Cutting edge: impairment of dendritic cells and adaptive immunity by Ebola and Lassa viruses. *J. Immunol.* **170**, 2797–2801 (2003).
24. Gupta, M., Mahanty, S., Ahmed, R. & Rollin, P. E. Monocyte-derived human macrophages and peripheral blood mononuclear cells infected with Ebola virus secrete MIP-1 α and TNF- α and inhibit poly-IC-induced IFN- α *in vitro*. *Virology* **284**, 20–25 (2001).
25. Ströher, U. *et al.* Infection and activation of monocytes by Marburg and Ebola viruses. *J. Virol.* **75**, 11025–11033 (2001).
26. Warfield, K. L. *et al.* Role of natural killer cells in innate protection against lethal Ebola virus infection. *J. Exp. Med.* **200**, 169–179 (2004).
27. Jahrling, P. B. *et al.* Evaluation of immune globulin and recombinant interferon- $\alpha 2b$ for treatment of experimental Ebola virus infections. *J. Infect. Dis.* **179** (Suppl. 1), 224–234 (1999).
28. Kash, J. C. *et al.* Global suppression of the host antiviral response by Ebola- and Marburgviruses: increased antagonism of the type I interferon response is associated with enhanced virulence. *J. Virol.* **80**, 3009–3020 (2006).
29. Khabar, K. S. *et al.* The α chemokine, interleukin 8, inhibits the antiviral action of interferon α . *J. Exp. Med.* **186**, 1077–1085 (1997).
30. Nathan, C. Neutrophils and immunity: challenges and opportunities. *Nature Rev. Immunol.* **6**, 173–182 (2006). **This is a timely and highly readable review of the sometimes neglected importance of neutrophils in innate and adaptive immunity.**
31. Chandran, K., Sullivan, N. J., Felbor, U., Whelan, S. P. & Cunningham, J. M. Endosomal proteolysis of the Ebola virus glycoprotein is necessary for infection. *Science* **308**, 1643–1645 (2005).
32. Schornberg, K. *et al.* Role of endosomal cathepsins in entry mediated by the Ebola virus glycoprotein. *J. Virol.* **80**, 4174–4178 (2006).
33. Dolnik, O. *et al.* Ectodomain shedding of the glycoprotein GP of Ebola virus. *EMBO J.* **23**, 2175–2184 (2004).
34. Sanchez, A. *et al.* Biochemical analysis of the secreted and virion glycoproteins of Ebola virus. *J. Virol.* **72**, 6442–6447 (1998).
35. Barrientos, L. G. & Rollin, P. E. Release of cellular proteases into the acidic extracellular milieu exacerbates Ebola virus-induced cell damage. *Virology* **358**, 1–9 (2007).
36. Mohamadadeh, M., Mohamadadeh, H., Brammer, M., Sestak, K. & Luftig, R. B. Identification of proteases employed by dendritic cells in the processing of protein purified derivative (PPD). *J. Immune Based Ther. Vaccines* **2**, 8 (2004).
37. Neumann, G. *et al.* Proteolytic processing of the Ebola virus glycoprotein is not critical for Ebola virus replication in nonhuman primates. *J. Virol.* **81**, 2995–2998 (2007).
38. Baize, S. *et al.* Defective humoral responses and extensive intravascular apoptosis are associated with fatal outcome in Ebola virus-infected patients. *Nature Med.* **5**, 423–426 (1999).
39. Geisbert, T. W. *et al.* Apoptosis induced *in vitro* and *in vivo* during infection by Ebola and Marburg viruses. *Lab. Invest.* **80**, 171–186 (2000).
40. Haring, J. S., Badovinac, V. P. & Harty, J. T. Inflaming the CD8 $^{+}$ T cell response. *Immunity* **25**, 19–29 (2006).
41. Chen, L. Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity. *Nature Rev. Immunol.* **4**, 336–347 (2004). **This review describes co-signalling molecules, a class of cell-surface glycoproteins that direct, modulate and fine-tune the TCR, and summarizes data indicating that T-cell functions can be promoted or suppressed on the basis of the functional outcome of co-stimulatory or co-inhibitory signals. The author emphasizes the appropriate time and location of these molecules directing either positive or negative signals to control priming, growth, differentiation and functional maturation of a T-cell immune response.**
42. Sharpe, A. H., Wherry, E. J., Ahmed, R. & Freeman, G. J. The function of programmed cell death 1 and its ligands in regulating autoimmunity and infection. *Nature Immunol.* **8**, 239–245 (2007). **This authoritative recent review highlights the crucial functions of PD1 and its ligands (PDL1 and PDL2) in regulating antimicrobial and self-reactive T-cell immune responses, and discusses potential therapeutic strategies in manipulating the immunological outcomes of such interactions.**
43. Carreno, B. M., Carter, L. L. & Collins, M. Therapeutic opportunities in the B7/CD28 family of ligands and receptors. *Curr. Opin. Pharmacol.* **5**, 424–430 (2005).
44. Dong, H. *et al.* B7-H1 determines accumulation and deletion of intrahepatic CD8 $^{+}$ T lymphocytes. *Immunity* **20**, 327–336 (2004).
45. Iwai, Y., Terawaki, S., Ikegawa, M., Okazaki, T. & Honjo, T. PD-1 inhibits antiviral immunity at the effector phase in the liver. *J. Exp. Med.* **198**, 39–50 (2003).
46. Barber, D. L. *et al.* Restoring function in exhausted CD8 T cells during chronic viral infection. *Nature* **439**, 682–687 (2006).
47. Trabattini, D. *et al.* B7-H1 is up-regulated in HIV infection and is a novel surrogate marker of disease progression. *Blood* **101**, 2514–2520 (2003).
48. Trautmann, L. *et al.* Upregulation of PD-1 expression on HIV-specific CD8 $^{+}$ T cells leads to reversible immune dysfunction. *Nature Med.* **12**, 1198–1202 (2006).
49. Day, C. L. *et al.* PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. *Nature* **443**, 350–354 (2006).
50. Reed, D. S., Hensley, L. E., Geisbert, J. B., Jahrling, P. B. & Geisbert, T. W. Depletion of peripheral blood T lymphocytes and NK cells during the course of Ebola hemorrhagic fever in cynomolgus macaques. *Viral Immunol.* **17**, 390–400 (2004).
51. Leroy, E. M. *et al.* Human asymptomatic Ebola infection and strong inflammatory response. *Lancet* **355**, 2210–2215 (2000).
52. Baize, S. *et al.* Inflammatory responses in Ebola virus-infected patients. *Clin. Exp. Immunol.* **128**, 163–168 (2002).
53. Badovinac, V. P. & Harty, J. T. Programming, demarcating, and manipulating CD8 $^{+}$ T-cell memory. *Immunol. Rev.* **211**, 67–80 (2006).
54. Haring, J. S., Badovinac, V. P., Olson, M. R., Varga, S. M. & Harty, J. T. *In vivo* generation of pathogen-specific Th1 cells in the absence of the IFN- γ receptor. *J. Immunol.* **175**, 3117–3122 (2005).
55. Kronenberg, M. Toward an understanding of NKT cell biology: progress and paradoxes. *Annu. Rev. Immunol.* **23**, 877–900 (2005).
56. Taniguchi, M., Seino, K. & Nakayama, T. The NKT cell system: bridging innate and acquired immunity. *Nature Immunol.* **4**, 1164–1165 (2003).
57. Tieb, J. *et al.* A novel dendritic cell subset involved in tumor immunosurveillance. *Nature Med.* **12**, 214–219 (2006).
58. Lee, S. J. *et al.* Interferon regulatory factor-1 is prerequisite to the constitutive expression and IFN- γ -induced upregulation of B7-H1 (CD274). *FEBS Lett.* **580**, 755–762 (2006).
59. Vitale, M. A. NK-dependent DC maturation is mediated by TNF α and IFN γ released upon engagement of the Nkp30 triggering receptor. *Blood* **106**, 566–571 (2005).
60. Wilson, J. A., Bray, M., Bakken, R. & Hart, M. K. Vaccine potential of Ebola virus VP24, VP30, VP35, and VP40 proteins. *Virology* **286**, 384–390 (2001).
61. Wilson, J. A. & Hart, M. K. Protection from Ebola virus mediated by cytotoxic T lymphocytes specific for the viral nucleoprotein. *J. Virol.* **75**, 2660–2664 (2001).
62. Pushko, P. *et al.* Recombinant RNA replicons derived from attenuated Venezuelan equine encephalitis virus protect guinea pigs and mice from Ebola hemorrhagic fever virus. *Vaccine* **19**, 142–153 (2000).
63. Xu, L. *et al.* Immunization for Ebola virus infection. *Nature Med.* **4**, 37–42 (1998).
64. Jones, S. M. *et al.* Live attenuated recombinant vaccine protects nonhuman primates against Ebola and Marburg viruses. *Nature Med.* **11**, 786–790 (2005).
65. Sullivan, N. J. *et al.* Immune protection of nonhuman primates against Ebola virus with single low-dose adenovirus vectors encoding modified GPs. *PLoS Med.* **3**, e177 (2006).
66. Bray, M. & Paragas, J. Experimental therapy of filovirus infections. *Antiviral Res.* **54**, 1–17 (2002).
67. Geisbert, T. W. *et al.* Evaluation in nonhuman primates of vaccines against Ebola virus. *Emerg. Infect. Dis.* **8**, 503–507 (2002).
68. Ignatyev, G. M., Agafonov, A. P., Streltsova, M. A. & Kashentseva, E. A. Inactivated Marburg virus elicits a nonprotective immune response in Rhesus monkeys. *J. Biotechnol.* **44**, 111–118 (1996).
69. Hevey, M., Negley, D., Geisbert, J., Jahrling, P. & Schmaljohn, A. Antigenicity and vaccine potential of Marburg virus glycoprotein expressed by baculovirus recombinants. *Virology* **239**, 206–216 (1997).
70. Wilson, J. A. *et al.* Epitopes involved in antibody-mediated protection from Ebola virus. *Science* **287**, 1664–1666 (2000). **This is the strongest of several demonstrations of antibody-mediated prevention of lethal filoviral disease in rodent models; here, monoclonal antibodies of differing specificities and *in vitro* functions are shown to protect in a mouse model of Ebola virus. Evidence that filovirus-specific antibodies (either monoclonal or polyclonal) can prevent disease in non-human primates is still lacking (for example, reference 76).**
71. Gupta, M., Mahanty, S., Bray, M., Ahmed, R. & Rollin, P. E. Passive transfer of antibodies protects immunocompetent and immunodeficient mice against lethal Ebola virus infection without complete inhibition of viral replication. *J. Virol.* **75**, 4649–4654 (2001).
72. Parren, P. W., Geisbert, T. W., Maruyama, T., Jahrling, P. B. & Burton, D. R. Pre- and postexposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. *J. Virol.* **76**, 6408–6412 (2002).

73. Martini, G. A. & Siebert, R. Marburg virus disease. (Springer-Verlag Berlin, New York, 1971). **This is a classic monograph that contains chapters on the clinical presentation, treatment efforts and discovery of causative agent in the first recognized filovirus outbreak in Europe in 1967. Because subsequent Marburg virus outbreaks have occurred in African sites poorly served by advanced medical care, this remains the best description of Marburg-virus disease in humans, and is updated by one of the key 1967 scientists in reference 3.**
74. Mupapa, K. *et al.* Treatment of Ebola hemorrhagic fever with blood transfusions from convalescent patients. *Int. J. Infect. Dis.* **179** (Suppl. 1), 18–23 (1999).
75. Gupta, M. *et al.* Persistent infection with Ebola virus under conditions of partial immunity. *J. Virol.* **78**, 958–967 (2004).
76. Oswald, W. B. *et al.* Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. *PLoS Pathog.* **3**, e9 (2007).
77. Burnett, J. C., Henchal, E. A., Schmaljohn, A. L. & Bavari, S. The evolving field of biodefense: therapeutic developments and diagnostics. *Nature Rev. Drug Discov.* **4**, 281–297 (2005).
78. Sullivan, N. J., Sanchez, A., Rollin, P. E., Yang, Z. Y. & Nabel, G. J. Development of a preventive vaccine for Ebola virus infection in primates. *Nature* **408**, 605–609 (2000). **This reference provides the earliest demonstration of a genetic vaccine capable of preventing Ebola-virus disease in non-human primates. The authors' subsequent studies showed glycoprotein antigen expressed in replication-defective adenovirus to be key ingredient.**
79. Riemenschneider, J. *et al.* Comparison of individual and combination DNA vaccines for *B. anthracis*, Ebola virus, Marburg virus and Venezuelan equine encephalitis virus. *Vaccine* **21**, 4071–4080 (2003).
80. Bukreyev, A. *et al.* A single intranasal inoculation with a paramyxovirus-vectored vaccine protects guinea pigs against a lethal-dose Ebola virus challenge. *J. Virol.* **80**, 2267–2279 (2006).
81. Bukreyev, A. *et al.* Successful topical respiratory tract immunization of primates against Ebola virus. *J. Virol.* **81**, 6378–6388 (2007).
82. Daddario-DiCaprio, K. M. *et al.* Postexposure protection against Marburg haemorrhagic fever with recombinant vesicular stomatitis virus vectors in non-human primates: an efficacy assessment. *Lancet* **367**, 1399–1404 (2006).
83. Feldmann, H. *et al.* Effective post-exposure treatment of Ebola infection. *PLoS Pathog.* **3**, e2 (2007).
84. Ebihara, H. *et al.* Molecular determinants of Ebola virus virulence in mice. *PLoS Pathog.* **2**, e73 (2006).
85. Swanepoel, R. *et al.* Experimental inoculation of plants and animals with Ebola virus. *Emerg. Infect. Dis.* **2**, 321–325 (1996).
86. Yao, S. & Chen, L. Reviving exhausted T lymphocytes during chronic virus infection by B7-H1 blockade. *Trends. Mol. Med.* **12**, 244–246 (2006).
87. Leroy, E. M. *et al.* Fruit bats as reservoirs of Ebola virus. *Nature* **438**, 575–576 (2005).
88. Feldmann, H., Slenczka, W. & Klenk, H. D. Emerging and reemerging of filoviruses. *Arch. Virol. Suppl.* **11**, 77–100 (1996).
89. Townner, J. S. *et al.* Marburgvirus genomics and association with a large hemorrhagic fever outbreak in Angola. *J. Virol.* **80**, 6497–6516 (2006).
90. Jahrling, P. B. *et al.* Experimental infection of cynomolgus macaques with Ebola-Reston filoviruses from the 1989–1990 U.S. epizootic. *Arch. Virol. Suppl.* **11**, 115–134 (1996).
91. Bwaka, M. A. *et al.* Ebola hemorrhagic fever in Kikwit, Democratic Republic of the Congo: clinical observations in 103 patients. *J. Infect. Dis.* **179** (Suppl. 1), 1–7 (1999). **This is a good overview, by an international team, of the clinical presentation of human Ebola-virus disease in a sizeable and deadly outbreak.**
92. Geisbert, T. W. *et al.* Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: a study in rhesus monkeys. *Lancet* **362**, 1953–1958 (2003).
93. Borio, L. *et al.* Hemorrhagic fever viruses as biological weapons: medical and public health management. *JAMA* **287**, 2391–2405 (2002).
94. Hevey, M. *et al.* Marburg virus vaccines: comparing classical and new approaches. *Vaccine* **20**, 586–593 (2001).
95. Chepurinov, A. A. *et al.* Attempts to develop a vaccine against Ebola fever. *Vopr. Virusol.* **40**, 257–260 (1995) (in Russian).
96. Bray, M., Davis, K., Geisbert, T., Schmaljohn, C. & Huggins, J. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. *J. Infect. Dis.* **178**, 651–661 (1998). **This paper describes derivation of a mouse-adapted variant of ZEBOV and provides evidence of many similarities between mouse and primate disease. That several subsequent studies have demonstrated differences between mouse and monkey disease manifested in the greater difficulty in protecting monkeys with vaccines and therapies, the selected use of the mouse model has not been negated.**
97. Volchkov, V. E. *et al.* Recovery of infectious Ebola virus from complementary DNA: RNA editing of the GP gene and viral cytotoxicity. *Science* **291**, 1965–1969 (2001).
98. Mellquist-Riemenschneider, J. L. *et al.* Comparison of the protective efficacy of DNA and baculovirus-derived protein vaccines for Ebola virus in guinea pigs. *Virus. Res.* **92**, 187–193 (2003).
99. Vanderzanden, L. *et al.* DNA vaccines expressing either the GP or NP genes of Ebola virus protect mice from lethal challenge. *Virology* **246**, 134–144 (1998).
100. Kobinger, G. P. *et al.* Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. *Virology* **346**, 394–401 (2006).
101. Swenson, D. L. *et al.* Virus-like particles exhibit potential as a pan-filovirus vaccine for both Ebola and Marburg viral infections. *Vaccine* **23**, 3033–3042 (2005).
102. Hevey, M., Negley, D. & Schmaljohn, A. Characterization of monoclonal antibodies to Marburg virus (strain Musoke) glycoprotein and identification of two protective epitopes. *Virology* **314**, 350–357 (2003).
103. Takada, A. *et al.* Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. *J. Virol.* **77**, 1069–1074 (2003).
104. Jeffers, S. A., Sanders, D. A. & Sanchez, A. Covalent modifications of the Ebola virus glycoprotein. *J. Virol.* **76**, 12463–12472 (2002).
105. Volchkov, V. E., Volchkova, V. A., Dolnik, O., Feldmann, H. & Klenk, H. D. Polymorphism of filovirus glycoproteins. *Adv. Virus Res.* **64**, 359–381 (2005).
106. Sanchez, A., Trappier, S. G., Mahy, B. W., Peters, C. J. & Nichol, S. T. The virion glycoproteins of Ebola viruses are encoded in two reading frames and are expressed through transcriptional editing. *Proc. Natl Acad. Sci. USA* **93**, 3602–3607 (1996).
107. Manicassamy, B., Wang, J., Jiang, H. & Rong, L. Comprehensive analysis of Ebola virus GP1 in viral entry. *J. Virol.* **79**, 4793–4805 (2005).
108. Weissenhorn, W., Carfi, A., Lee, K. H., Skehel, J. J. & Wiley, D. C. Crystal structure of the Ebola virus membrane fusion subunit, GP2, from the envelope glycoprotein ectodomain. *Mol. Cell* **2**, 605–616 (1998).
109. Kuhn, J. H. *et al.* Conserved receptor-binding domains of Lake Victoria marburgvirus and Zaire ebolavirus bind a common receptor. *J. Biol. Chem.* **281**, 15951–15958 (2006).
110. Yang, Z. Y. *et al.* Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. *Nature Med.* **6**, 886–889 (2000).
111. Simmons, G., Wool-Lewis, R. J., Baribaud, F., Netter, R. C. & Bates, P. Ebola virus glycoproteins induce global surface protein down-modulation and loss of cell adherence. *J. Virol.* **76**, 2518–2528 (2002).
112. Bukreyev, A., Volchkov, V. E., Blinov, V. M. & Netesov, S. V. The GP-protein of Marburg virus contains the region similar to the 'immunosuppressive domain' of oncogenic retrovirus P15E proteins. *FEBS Lett.* **323**, 183–187 (1993).

Acknowledgements

The views, opinions and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army or Johns Hopkins University position, policy, or decision unless designated by other documentation. This work was supported in part by the Defense Threat Reduction Agency.

Competing interests statement

The authors declare no competing financial interests.

DATABASES

The following terms in this article are linked online to:

Entrez Gene: <http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=gene>

B7-H1 | CD40 | CD86 | DC-SIGN | ICAM3 | IFN α | IFN β | IFN γ | IL-12 | L-SIGN

Entrez Genome: <http://www.ncbi.nlm.nih.gov/sites/entrez?Db=genome>

MARV | SEBOV | ZEBOV

Access to this links box is available online.